$Anavex Life Sciences (AVXL.US)$ Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio Anavex Life Sciences (Nasdaq: AVXL) has been granted a new U.S. Patent (No. 12,180,174) for crystalline forms of ANAVEX®2-73 (blarcamesine) dihydrogen phosphate salt. The patent covers crystalline forms, freebase, transdermal patches, and enteric coated oral dosage forms for neuroprotection and treatment of neuro...
$Anavex Life Sciences (AVXL.US)$Reuters Just Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio
$Anavex Life Sciences (AVXL.US)$Reuters· just New Phase Iib/III Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Here are the levels to watch as AVXL continues to drift lower after the large move last week. Support at 10.33 for now. 11.55 level to get over. $Anavex Life Sciences (AVXL.US)$
1
Report
Rhiox
:
looking at the day chart, still to be on an uptrend even after this pullback. my opinion this needs these pull backs for a healthy uptrend to continue.
Anavex Life Sciences Stock Forum
$Anavex Life Sciences (AVXL.US)$
Breakthrough: Anavex Alzheimer's Treatment Halts Disease Progression by Over One-Third
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences (Nasdaq: AVXL) has been granted a new U.S. Patent (No. 12,180,174) for crystalline forms of ANAVEX®2-73 (blarcamesine) dihydrogen phosphate salt. The patent covers crystalline forms, freebase, transdermal patches, and enteric coated oral dosage forms for neuroprotection and treatment of neuro...
Just
Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio
New Phase Iib/III Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
$Anavex Life Sciences (AVXL.US)$
I would like to wish everyone a Happy New Year
No comment yet